What did @marioramirezfit actually say?
The caption does the heavy lifting here because the transcript is largely unintelligible, a mix of garbled Spanish and English that doesn't produce coherent medical claims. From what can be reconstructed, the creator argues that a "normal" TSH result doesn't mean a Hashimoto's patient feels well, that levothyroxine corrects a hormonal signal but not the underlying autoimmune process, and that chronic stress amplifies the condition. The hashtags, BPC-157, KPV, MOTSc, and Selank, strongly imply peptide therapy is being positioned as a solution, even if the transcript never gets there clearly.
The caption's framing is worth quoting directly: "El médico te muestra el TSH en rango. Tú sigues con fatiga, niebla mental y peso que no se mueve. Los dos tienen razón." That's the clearest claim in the entire piece: both the doctor and the patient are right, and the gap between them is the real problem. That part is actually worth unpacking seriously.
Does the science back this up?
The core premise, that a normal TSH doesn't guarantee symptom resolution in Hashimoto's thyroiditis, is supported by solid evidence. A 2021 meta-analysis by Idrees et al. in Thyroid confirmed that a subset of patients treated to TSH targets still report persistent fatigue, cognitive symptoms, and weight changes. The autoimmune mechanism is also well-established: Hashimoto's involves T-cell mediated destruction of thyroid follicular cells, and TPO antibodies continue their activity regardless of whether TSH is corrected (Ragusa et al., 2019, Endocrine).
Where things get shakier is the implied jump to peptides. MOTSc has early mitochondrial data in mouse models (Lee et al., 2015, Cell Metabolism), but no published human trials exist for autoimmune thyroid disease. Selank has anxiolytic data from Russian literature, mostly small and not replicated in Western peer review. KPV has some preliminary anti-inflammatory cell culture data. None of these have been tested in Hashimoto's patients in any controlled setting.
What did they get wrong (or right)?
Credit where it's due: the observation that TSH normalization and symptom resolution are not the same thing is correct and genuinely underappreciated in primary care settings. Studies show roughly 5-10% of treated hypothyroid patients continue to have persistent symptoms (Saravanan et al., 2002, JCEM). The autoimmune framing is also accurate. Hashimoto's is not simply a hormone deficiency disease.
What's wrong, or at minimum unsubstantiated, is the implicit suggestion that the listed peptides address this gap. Listing BPC-157, KPV, MOTSc, and Selank in the hashtags of a Hashimoto's video without any published human evidence connecting them to autoimmune thyroid outcomes is speculative at best and misleading at worst. No peptide on that list has an approved indication for thyroid autoimmunity. The stress-gut axis claim in the caption fragments is plausible as a general concept but presented without any specific mechanism or citation context.
What should you actually know?
If your TSH is normal but you still feel terrible, that's a real clinical scenario and you deserve a real workup. Options supported by evidence include: testing free T3 and T4 (not just TSH), checking TPO and thyroglobulin antibodies, considering a selenium supplementation trial (Drutel et al., 2013, Clinical Endocrinology found 200 mcg/day reduced TPO antibody titers), evaluating for comorbid conditions like anemia or sleep apnea, and in some cases discussing T3/T4 combination therapy with an endocrinologist.
Peptides are a different conversation entirely. Some have interesting early-stage data. None are FDA-approved treatments for Hashimoto's. If a telehealth provider is recommending peptide stacks for autoimmune thyroid disease, ask them specifically what human trial data they're drawing from. The honest answer right now is that there isn't much. That doesn't mean the research won't develop, but it does mean anyone selling certainty here is ahead of the evidence.